ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 159 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2018. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $14,000 | -78.5% | 345 | -77.1% | 0.00% | – |
| Q3 2019 | $65,000 | +170.8% | 1,504 | +294.8% | 0.00% | – |
| Q2 2019 | $24,000 | -11.1% | 381 | -2.6% | 0.00% | – |
| Q1 2019 | $27,000 | +107.7% | 391 | +28.6% | 0.00% | – |
| Q4 2018 | $13,000 | -35.0% | 304 | +14.7% | 0.00% | – |
| Q3 2018 | $20,000 | +233.3% | 265 | +219.3% | 0.00% | – |
| Q2 2018 | $6,000 | +50.0% | 83 | -1.2% | 0.00% | – |
| Q1 2018 | $4,000 | 0.0% | 84 | -5.6% | 0.00% | – |
| Q4 2017 | $4,000 | +33.3% | 89 | +81.6% | 0.00% | – |
| Q3 2017 | $3,000 | -62.5% | 49 | -62.9% | 0.00% | – |
| Q2 2017 | $8,000 | -11.1% | 132 | -4.3% | 0.00% | – |
| Q1 2017 | $9,000 | -43.8% | 138 | -42.5% | 0.00% | – |
| Q4 2016 | $16,000 | 0.0% | 240 | 0.0% | 0.00% | – |
| Q3 2016 | $16,000 | +1500.0% | 240 | +471.4% | 0.00% | – |
| Q2 2016 | $1,000 | – | 42 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |